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Abstract: Will write once decide on Journal.  
Background.  
HIV incidence in the United States (US) is slowly declining over time, but an estimated 40,000 new infections 
still occur each year.1 Since persons living with HIV (PLwHIV) who achieve virologic suppression have 
effectively no risk of transmitting the virus to others,2-4 linkage to care and initiation of antiretroviral therapy have 
likely contributed greatly to this declining trend. However, the benefits of “treatment as prevention” and other 
new biomedical prevention technologies5,6 are not distributed equally across subpopulations affected by HIV. 
Black communities continue to experience the most severe burden of HIV rates of all racial/ethnic groups in the 
US, with Black men who have sex with men (MSM) most disproportionately impacted.7 In 2016, Black MSM 
accounted for 26%  of the 39,782 new HIV diagnoses in the US. Furthermore, while the overall rate among Black 
MSM has not changed, there was a 30% increase in HIV infection rates among those ages 25-34 between 2011 
and 2015.7 Modeling studies have estimated that if the current trends do not change, one in two Black MSM will 
be diagnosed with HIV in his lifetime8, and that if current incidence rates persist, 40% of Black MSM will be 
HIV-infected by age 30.9  
 
The low uptake of pre-exposure prophylaxis (PrEP) among Black MSM to date is likely an important contributor 
to this persistent disparity in HIV incidence.10,11 Since FDA approval of oral emtricitabine/tenofovir disoproxil 
fumarate (FTC/TDF) as PrEP in 2012, the number of PrEP users has steadily increased – but utilization is 
concentrated among White MSM.12,13 While Black MSM in the US have the highest rate of HIV infections, it is 
estimated that only about 10% of PrEP users are Black.12 In 2015, of 813,970 MSM with indications for PrEP, 
38% were Black, 29% were White, and 27% were Latino.14 An evaluation of the PrEP care continuum on an 
Atlanta cohort of MSM (n=562) found that while Black MSM were equally likely to report awareness of and 
willingness to use PrEP compared to White MSM, Black MSM were less likely to receive a PrEP prescription 
(24.2 vs. 34.8%) and achieve protective levels (12.3% vs. 17.8%).15  
 
Further complicating the reduction of HIV among the highest risk groups is the relationship between HIV and 
other sexually transmitted infections (STIs). Individuals with active STIs are at greater susceptibility for HIV 
  
infections and vice versa.16-18 Among MSM, STIs have dramatically increased in the last decade.19,20 There is 
general concern that expanded use of PrEP may lead to increased incidence of bacterial STIs, but available data 
thus far have been mixed.21. The mechanism by which PrEP use could lead to higher STI incidence may be 
explained by the sexual behavior of those who initiate PrEP (men who already engage in condomless anal sex 
(CAI) and/or have multiple sexual partners) who seek HIV prevention due to their established patterns of sexual 
behavior 20. Other non-causal, potentially confounding, reasons include the increased frequency of screening and 
diagnosis of asymptomatic infections as part of the clinical standards of PrEP use.22  However, limited data exist 
regarding STI risk in Black MSM PrEP users, despite the fact that Black MSM have been identified as one of the 
highest risk groups for HIV and other STI acquisition.7,8,23,24 
 
We sought to examine STI incidence among PrEP users by studying a unique cohort of Black MSM recruited for 
HIV Prevention Trials Network (HPTN) Study 073 (clinicaltrials.gov: NCT01808352). This multi-site, open-label 
demonstration study explored whether provision of a structural intervention (client-centered care coordination, or 
C4) could improve acceptance of and adherence to oral FTC/TDF among Black MSM. The C4 model integrates 
an evidence-based, public health strategy with a self-determination theory-based approach to counseling and 
client engagement.25,26 Objectives of the parent study included description of the initiation, acceptability, safety, 
and feasibility of PrEP for Black MSM. The purpose of this secondary analysis  was to characterize the 
relationship between PrEP uptake and use and incident STIs among participants enrolled in HPTN 073. 
 
Methods 
Parent Study 
HPTN 073 enrolled 226 HIV-uninfected Black MSM between August 2013 and September 2014 in three US 
cities: Los Angeles, CA; Washington, DC; and Chapel Hill, NC. To be eligible, participants had to provide 
informed consent, be over age 18, self-identify as male at birth and Black (multiracial/multiethnic men were also 
eligible), and self-report at least one of the following HIV risk behaviors or characteristics: CAI with a male 
partner, anal intercourse with more than three male partners, exchanging any anal sex with a male partner for 
money, gifts, shelter or drugs, anal intercourse with a male partner while using drugs or alcohol, or having a male 
  
sex partner and an STI diagnosis in past six months. In addition, all participants had to be clinically eligible to 
receive FTC/TDF based on laboratory testing.27  
 
At screening, all participants were offered HIV and STI testing along with C4 (which included referrals for 
healthcare and prevention services and harm reduction counseling). In addition, participants were offered 
FTC/TDF and all related clinical testing free of charge. Participants could choose to initiate oral PrEP at any study 
visit until week 48, per their request and upon confirmation of a non-reactive antigen/antibody combination HIV 
test. Participants could also choose to discontinue PrEP at any point during the course of the study. Following 
informed consent and enrollment, participants had study visits at weeks 4, 8, and 13; visits occurred quarterly 
thereafter, up to 12 months. At weeks 26 and 52, men were tested for syphilis, and rectal and urethral gonorrhea 
and chlamydia. Rapid plasma reagin (RPR) testing for syphilis was obtained from plasma specimens; reactive 
titers were confirmed using a treponemal-specific assay per local testing protocols. Testing for Chlamydia 
Trachomatis (CT) and Neisseria Gonorrhoeae (NG) were performed for urine and rectal swab samples using the 
Aptima Combo 2 Assay for CT/NG assay (Hologic, San Diego, CA) by the HPTN Laboratory Center.  
Pharyngeal STIs were not specifically tested for per protocol but were reported as adverse events (AEs), if 
detected. At each visit, participants completed an audio-computer assisted self-interview (ACASI). 
 
Safety Monitoring 
The HPTN 073 study protocol was approved by the institutional review boards of University of California at Los 
Angeles, University of North Carolina at Chapel Hill, and George Washington University. All study participants 
provided written, informed consent and completed an informed consent assessment to ensure a thorough 
understanding of the study prior to enrollment. 
 
Measures 
Sexual risk behaviors: At baseline and each follow-up ACASI, participants were asked about engagement in 
insertive and receptive condomless anal intercourse (CAI) with primary (main) and casual male partners. 
  
Engagement in CAI (any, insertive and receptive) was dichotomized; participants reporting > 1 instance in CAI in 
the past 3 months vs. participants reporting no instances of CAI. 
 
PrEP adherence was examined in two ways: self-report data were collected by interview instrument and blood 
levels indicating short term (Plasma or PBMC) adherence >4 pills per week. The Visual Analogue Scale (VAS) 
was used to measure self-reported adherence to PrEP in the past 30-days.28 Patients were presented with a line 
anchored at 0% and 100%; provided with examples of what 0, 50%, and 100% adherence would represent; and 
asked to assess their own PrEP medication adherence. The biological measure of short-term PrEP adherence was 
defined as those who met the 90% sensitivity threshold for ≥4 doses of FTC/TDF per week from any of the two 
samples types (Plasma and PBMC) related to tenofovir (TFV) and emtricitabine (FTC) measurements: ≥4.2 
ng/mL for TFV and ≥4.6 ng/mL for FTC in plasma; 9.9 fmol/106 for TFV diphosphate (TFV-DP) and 0.4 
fmol/106 for FTC triphosphate in PBMCs. These measures of adherence for plasma and PBMC samples were 
established by the directly observed dosing study, HPTN 066.29  
 
Statistical Analysis 
Following univariate description of the participants’ demographic, behavioral, and clinical characteristics at 
baseline, logistic regression was used to examine the unadjusted and adjusted associations between STI incidence 
and PrEP uptake adjusting for site differences. Incidence rates and confidence intervals were calculated based on 
a Poisson distribution. Person-years (PY) of follow-up time were calculated to the first STI diagnosis or last STI 
date from either the PrEP acceptance date or study enrollment date, depending if the participant accepted PrEP or 
not. Associations between age, PrEP acceptance, sexual behaviors, and new STI cases were evaluated using 
generalized estimating equations (GEE) to account for the repeated observations at weeks 26 and 52 with 
adjusting for site differences. Among participants who acquired HIV during study follow-up, STI diagnoses are 
not counted after HIV seroconversion, as different psychosocial and physiologic states may obscure the 
relationship between PrEP and STIs. All analyses were conducted in using SAS version 9.4 (SAS Institute, Cary, 
NC).  
 
  
Results. 
Characteristics of Participants. 
Detailed characteristics of participants in HPTN 073 are described elsewhere.30 Briefly, of 226 enrolled 
participants, 86% self-identified as Black or African American only, 25% had a high school diploma or less, 48% 
reported an annual income of less than $20,000, 73% and 20% identified as gay or bisexual, respectively. The 
median age was 26 years (interquartile range [IQR] 23 to 32), and 91 men (40.3%) were age 25 or younger. 
 
Baseline and Incident STIs  
STI prevalence was 14.2% at the baseline visit. The most common STI at baseline was chlamydia (10.2%; 1.8% 
urethral and 9.1% rectal) followed by gonorrhea (5.3%; 0.9% urethral and 4.6% rectal) and syphilis (1.3%). These 
proportions did not change substantially at week 26 (16.2%) or week 52 (18.2%) (P = 0.85) (Figure 1). Rectal 
STIs accounted for the largest proportion of infections at all three visits (11.5%, 11.8%, and 9.6%). At the 
baseline visit, men younger than 25 years old had a higher STI prevalence than older men (25.3% versus 6.7%), 
and those rates translated into a 4 times higher odds of an STI in younger men (odds ratio [OR] 4.39, 95% 
confidence interval [CI]: 1.91, 10.11).  
 
Sixty men (26.5%) acquired an STI during follow-up, and 9 men (4%) had an STI at both follow-up visits. 
Incident STIs by visit and short term PrEP adherence demonstrated by blood levels at each visit are described in 
Table 1. Regardless of PrEP acceptance, compared to men who were 25 years and older, those men younger than 
25 were more likely to have STIs at both 26 (9.2% (11/120) versus 26.5% (22/83)) and 52 weeks (16.0% (19/119) 
versus 22.0% (18/82)). At week 26, those who accepted PrEP had similar rates of STIs whether or not they 
reported any CAI in the prior 3 months (19.3% any CAI; 15.5% no CAI). Among the 4 participants at week 26 
who were diagnosed with an STI (3 of whom had rectal infections) and had not opted to take PrEP, none reported 
CAI in the past 3 months – suggesting the potential for reporting bias. At week 52, 18 participants who denied 
CAI in the past 3 months were diagnosed with a new STI (9 of which were rectal infections), including 15 men 
who accepted PrEP and 3 who did not.  
 
  
Over the entire study follow-up period, there was an STI incidence rate of 34.2 cases per 100 person-years (95% 
CI: 27.4, 42.9; Table 2). No statistically significant differences in STI incidence were found by study visit week 
or by PrEP acceptance. Among those men with at least 1 incident STI, adherence (both self-report and as 
measured by PK) was low at both 26 and 52 weeks (26.7% self reported adherence >=60%; 28.4% had PK short 
term adherence >= 4 days/week). 
 
Correlates of Incident STIs 
Several characteristics were associated with having an incident STI prior to adjustment for confounders as shown 
in Table 3, including being less than 25 years old, having a prevalent STI at baseline, and having greater than the 
mean number of minutes of C4 contact time. In the adjusted analysis, only the presence of a baseline STI 
diagnosis  (OR 4.23, 95% CI: 1.82, 9.87; p<0.001) and additional minutes of C4 (OR 1.03, 95% CI: 1.00, 1.06; 
p=0.027) remained associated with having an incident STI. We saw no statistically significant association 
between PrEP uptake, self-reported PrEP adherence, or PrEP adherence measured by PK levels (Table 3). 
 
Changes in Condomless Anal Intercourse 
There was no statistically significant change in self-reported insertive or receptive CAI over time. Nearly half of 
participants (45.8%) reported insertive CAI at baseline, which remained stable during follow-up (p=0.096). 
Slightly fewer men (44.9%) reported receptive CAI at baseline, which also remained stable during follow-up 
(p=0.180). Overall, the proportion of participants report CAI was lower for those not accepting PrEP compared to 
those aceepting PrEP at all time points (Table 4). Decreased rates of CAI (both receptive and insertive were 
observed from baseline through week 52) among both men accepting and not accepting PrEP. 
 
Relationship between incident HIV infections and STIs 
Overall there were 8 incident HIV infections diagnosed during the study. Two of these men were diagnosed with 
incident STIs at the time of seroconversion (one man who accepted PrEP diagnosed with syphilis and one man 
who did not accept PrEP was diagnosed with urethral gonorrhea). Two participants who seroconverted were 
diagnosed with chlamydia at basline (one rectal and one urethral infection). 
  
 
Discussion 
To our knowledge, this is the first study to evaluate longitudinal acquisition of STIs in a sample of US Black 
MSM being offered PrEP. Overall, 26.5% of participants in HPTN 073 were diagnosed with an STI over the 
course of the study, a rate lower than what was seen in other recent PrEP clinical trials and demonstration 
projects.31,32  While direct comparisons cannot be made – particularly given that the majority of previous studies 
enrolled few Black MSM 31,32 – these results provide valuable insight into ongoing risk behaviors among the 
population most impacted by HIV infection in the US.  
 
In registrational trials of FTC/TDF for PrEP, a high incidence of STIs was observed but there was no conclusive 
evidence for risk compensation among PrEP users. Indeed, some studies reported a decline in key metrics of STI 
risk (e.g. decreased number of sex partners or frequency of condomless sex).32-35 In IPERGAY, a double blind, 
placebo controlled trial of coital event-based PrEP for MSM, the proportions of participants with a new STI 
during follow-up were not significantly different (41% in the FTC/TDF group and 33% in the placebo group).36 
Similarly, even though there was a high incidence of STIs among participants in the US PrEP Demonstration 
Project, the rate did not increase over time while people were on PrEP.31 However, other studies suggest higher 
rates of STIs among MSM who use PrEP compared to non-PrEP users.37-39 This may simply be a function of the 
risk profile of early adopters of PrEP – a population of MSM who might already engage more often in CAI and/or 
have multiple sex partners.20 An apparent increased STI incidence among PrEP users could also be an artifact of 
more frequent and consistent screening in this population.22  
 
The low overall rate of STI acquisition we observed is encouraging as efforts to increase uptake of PrEP in this 
population expands. Nationwide, rates of STIs are 4.6, 6.6 and 8.9 time higher in Black men compared to White 
men for syphilis, chlamydia and gonorrhea, respectively.23 A recent cohort study found that among MSM 
accessing medical care at a Boston community health center between 2005-2015, STI diagnoses increased more 
than 8-fold. Though Black MSM made up only 6% of the participants, multivariable analyses demonstrated that 
being an MSM of color was independently associated with being diagnosed with a new STI.40 Thus, when 
  
situated within the context of disparate rates of STIs reported among Black MSM compared with MSM of other 
races41, the low overall rates of STIs are encouraging as efforts to increase uptake of PrEP in this population 
expands.  Of note, the men in this study were offered a culturally tailored behavioral intervention, C4, which may 
have attenuated their sexual risk behavior.  
 
Being younger than 25 quadrupled the odds of having an STI at screening, and those with STIs at baseline were 
more likely to have an incident STI at any follow-up visit. Black MSM with STIs at PrEP initiation may require 
additional counseling regarding sexual risk behaviors during follow-up. While a recent study showed that on 
demand post-exposure prophylaxis (PEP) with doxycycline reduced the incidence of chlamydia infection and 
syphilis in high risk MSM enrolled in a PrEP study42, the utility of this strategy for Black MSM, particularly its 
durability and impact on antibiotic resistance, requires further investigation. 
 
The overall low adherence to PrEP among those Black MSM in this study with incident STIs is concerning. Given 
that MSM with a history of syphilis or anorectal STIs have a greater risk of subsequent HIV acquisition43-45, 
additional efforts to develop effective adherence interventions for Black MSM on PrEP is critical.  This finding is 
echoed by a recent 24-week demonstration project PrEP among young MSM (aged 18-22 years), which found that 
at all times, median TFV-DP levels for Black MSM participants were below the protective threshold of greater 
than or equal to four pills per week.46 
 
Rates of STIs were similar among those who chose to start PrEP in this study compared to those who declined 
PrEP, with no increase in incidence over time. While this aligns with the lack of increase in participant self-
reported CAI over time, self-report of sexual risk behaviors may not always be an accurate reflection of risk. 
Indeed, we found that nearly 50% of participants at both week 26 and 52 who reported no CAI in the past 3 
months, were diagnosed with a new STI. This echoes previous findings from a cohort of 485 young Black MSM 
recruited in Jackson, Mississippi, among whom 19.4% of rectal STI infections would have been missed if 
screening had not occurred on those denying any receptive anal sex.47 
 
  
Men who had more minutes of C4 were more likely to have an incident STI during study follow-up. This may 
indicate that those men had more complex social situations and higher needs, including ongoing risk behaviors for 
STI acquisition that required more counseling time and referalls. Among Black MSM, factors such as social 
isolation and experiences of racism and homophobia have been shown to drive sexual risk taking.48-50 Further, 
structural factors, including financial hardship, incarceration and unstable housing have been associated with 
increased STIs among Black MSM.48,51 Additional analyses unpacking the time spent on care coordination 
activites to address participants’ sexual health needs will be informative to understand how to tailor future 
interventions to address both ongoing risk and additional psychosocial stressors experienced by this population. 
 
There were some limitations in this study that must be mentioned. Screening for STIs only occurred at baseline 
and weeks 26 and 52 study visits, thus potentially underestimating the number of STIs among participants. 
Participants were queried at each study visit (weeks 4, 8, and quarterly thereafter, up to 12 months) regarding any 
interim testing they had done, resulting in our awareness of 5 additional diagnoses and 3 cases of presumptive 
treatment at other clinic sites. Recent data and CDC guidelines suggest more frequent testing (every 3 months) 
than was provided in this study, is warranted for those on PrEP.27 In addition, STI screening in this study did not 
include sampling for pharyngeal gonorrhea, which should be encouraged moving forward, given concerns 
regarding the possible role of pharyngeal gonococcal infection, as a reservoir of antimicrobial-resistant infection 
which could have future implications for the prevention and control of gonorrhea in MSM on PrEP.52-54  Further, 
as mentioned above, sexual risk behavior data collected by self-report. While ACASIs have been shown to 
minimize social desirability bias when reporting sexual risk behaviors55-57, the fact that many men who reported 
no CAI were diagnosed with new STIs is concerning. 
 
Conclusions 
The expansion of effective models of combination HIV and STI prevention, including PrEP, provides a unique 
and timely opportunity to address the lack of progress to date in reducing HIV incidence among Black MSM.58 
However, PrEP for Black MSM should not be delivered “in isolation” but as part of a combination prevention 
package that incorporates frequent STI screening and treatment and addresses Black MSM’s pervasive ongoing 
  
exposure to adverse social and structural conditions, as well as a confluence of individual factors that continue to 
impact their overall health. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1: STIs at Screening and Follow-up 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 1: Characteristics of Incident STIs by PrEP Acceptance and Visit 
 
Week 26 PrEP 
Accept % (n/N) 
Week 26 PrEP 
Not Accept % 
(n/N) 
Week 52 PrEP 
Accept % (n/N) 
Week 52 PrEP 
Not Accept % 
(n/N) 
Any STI 
 
17% (29/167) 
 
11% (4/36) 
 
19% (31/166) 
 
17% (6/35) 
Age     
     >25 10.6% (10/94) 3.8% (1/26) 15.6% (15/96) 17.4% (4/23) 
<25 26.0% (19/73) 30.0% (3/10) 22.9% (16/70) 16.7% (2/12) 
Baseline Any STI Diagnosis     
No 12.9% (18/139) 12.1% (4/33) 15.7% (22/140) 18.8% (6/32) 
Yes 39.3% (11/28) 0.0% (0/3) 34.6% (9/26) 0.0% (0/3) 
Any CAI (past 3 months)     
No 15.5% (11/71) 17.4% (4/23) 18.1% (15/83) 12.0% (3/25) 
Yes 19.3% (16/83) 0.0% (0/11) 17.8% (13/73) 37.5% (3/8) 
Any receptive CAI (past 3 months)     
No 17.2% (15/87) 14.8% (4/27) 15.7% (16/102) 11.5% (3/26) 
Yes 17.9% (12/67) 0.0% (0/7) 22.2% (12/54) 42.9% (3/7) 
Any insertive CAI (past 3 months)     
No 20.2% (18/89) 15.4% (4/26) 15.6% (15/96) 11.1% (3/27) 
Yes 13.8% (9/65) 0.0% (0/8) 21.7% (13/60) 50.0% (3/6) 
Any Alcohol/Drug use 2 hrs. before or 
during Sex (past 3 months) 
    
No 16.3% (16/98) 8.3% (2/24) 15.8% (16/101) 18.5% (5/27) 
Yes 19.6% (11/56) 20.0% (2/10) 21.8% (12/55) 16.7% (1/6) 
Self-Report adherence >60%     
No 22.6% (7/31) n/a 26.3% (5/19) n/a 
Yes 16.8% (18/107) n/a 15.7% (13/83) n/a 
PK short term adherence >4 days/week     
No 19.0% (11/58) n/a 17.1% (13/76) n/a 
Yes 16.7% (17/102) n/a 20.9% (18/86) n/a 
Average C4 minutes     
Mean (SD) 30 (7.8) 30 (7.8) 29 (6.3) 36 (15.2) 
Min, Max 20, 50 23, 41 16, 41 18, 60 
Median 29 28 28 31 
25th, 75th %tile 24, 34 25, 36 24, 34 30, 48 
  
Table 2. STI Incidence Rate by PrEP Acceptance 
 
 STI 
(n) 
Person -
years 
Incidence Rate (95% CI)  
per 100 person years 
 
P-Value 
Overall (all participants)           70      204.6                    34.2 (27.4, 42.9)  
     
All Weeks       0.4658 
Not on PrEP           11      39.2                    28.1 (15.5, 50.7)  
On PrEP           59      165.4                    35.7 (27.6, 46.0)  
     
Week 26     
Not on PrEP           5      20.2                    24.8 ( 10.3, 59.6)    0.4363 
On PrEP           28      77.3                    36.2 (25.0, 52.4)  
     
Week 52     
Not on PrEP           6      19.0                    31.5 ( 14.2, 70.2)     0.8048 
On PrEP            31      88.1                    35.2 (24.8, 50.0)  
     
  
 
Table 3. Correlates of Incident STIs 
 
At least one 
incident STI 
% (n/N) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Age    
     >=25 21.4% (27/126) Ref  
<25 38.6% (34/88) 2.39 (1.36, 4.20) 1.41 (0.60, 3.31) 
PrEP Acceptance    
Not on Prep 25.0% (10/40) 1.47 (0.73, 2.96)  
On Prep 29.3% (51/174) Ref  
Baseline Any STI Diagnosis    
No 24.0% (44/183) Ref  
Yes 54.8% (17/31) 3.20 (1.67, 6.11) 4.23 (1.82, 9.87) 
Any CAI (past 3 months)    
No 26.5% (27/102) Ref  
Yes 30.5% (29/95) 1.20 (0.69, 2.07)  
Any Receptive CAI (past 3 months)    
No 27.4% (32/117) Ref  
Yes 30.0% (24/80) 1.39 (0.79, 2.45)  
Any Insertive CAI (past 3 months)    
No 28.1% (34/121) Ref  
Yes 28.9% (22/76) 1.14 (0.67, 1.94)  
Any Alcohol/Drug 2 hrs. before or 
during Sex (past 3 months) 
   
No 27.3% (35/128) Ref  
Yes 30.4% (21/69) 1.34 (0.75, 2.40)  
Self-Report adherence >=60pct    
No 35.5% (11/31) Ref  
Yes 26.7% (28/105) 0.60 (0.27, 1.31)  
PK short term adherence >= 4 days/wk    
No 33.3% (21/63) Ref  
Yes 28.4% (29/102) 1.16 (0.65, 2.08)  
Average C4 minutes    
Mean (SD) 30 (9.5) 1.02 (1.00, 1.05)     1.03 (1.00, 1.06) 
Median(Q1,Q3) 28 (23,34)   
 
 
 
 
 
 
  
Table 4: Proportion of participants reporting condomless insertive anal sex (CAI) by PrEP acceptance 
and week on study. 
 
PrEP 
Acceptance 
 Baseline Visit Week 26 Week 52 
Yes Overall CAI 105/177 (59.3%) 84/156 (53.9%) 73/161 (45.3%) 
Insertive CAI 90/177 (50.9%) 65/156 (41.7%) 60/161 (37.3%) 
Receptive CAI 83/177 (46.9%) 68/156 (43.6%) 54/161 (33.5%) 
No  Overall CAI 19/48 (39.6%) 11/34 (32.4%) 10/38 (26.3%) 
Insertive CAI 13/48 (27.1%) 8/34 (23.5%) 8/38 (21.0%) 
Receptive CAI 18/48 (37.5%) 7/34 (20.6%) 8/38 (21.0%) 
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